Literature DB >> 8917020

Hormone replacement therapy in the menopause: a pro opinion.

H O Smith1, D N Kammerer-Doak, D M Barbo, G E Sarto.   

Abstract

The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.

Entities:  

Mesh:

Year:  1996        PMID: 8917020     DOI: 10.3322/canjclin.46.6.343

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  3 in total

1.  Mammography in New Hampshire: characteristics of the women and the exams they receive.

Authors:  P A Carney; M E Goodrich; D M O'Mahony; A N Tosteson; M S Eliassen; S P Poplack; S Birnbaum; B G Harwood; K A Burgess; B T Berube; W S Wells; J P Ball; M M Stevens
Journal:  J Community Health       Date:  2000-06

2.  Acute hazards to young children from residential pesticide exposures.

Authors:  M F Spann; J M Blondell; K L Hunting
Journal:  Am J Public Health       Date:  2000-06       Impact factor: 9.308

3.  Menopausal hormones and breast cancer in a biracial population.

Authors:  P G Moorman; H Kuwabara; R C Millikan; B Newman
Journal:  Am J Public Health       Date:  2000-06       Impact factor: 9.308

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.